The assessment of plasma asprosin levels in acute coronary artery disease and its correlation with HEART score

Abdullah Algin 1, Serdar Özdemir 1 * , Hatice Şeyma Akça 1, Nihat Müjdat Hökenek 2, Kamil Kokulu 3, Mehmet Özgür Erdoğan 4, Önder Yumrutaş 5
More Detail
1 Department of Emergency Medicine, University of Health Sciences, Umraniye Training and Research Hospital, Istanbul, Turkey
2 Department of Emergency Medicine, University of Health Sciences, Kartal Dr. Lutfi Kırdar Training and Research Hospital, Istanbul, Turkey
3 Department of Emergency Medicine, Aksaray University, Aksaray, Turkey
4 Department of Emergency Medicine, Bahcesehir University, Istanbul, Turkey
5 Department of Medical Biology, Adıyaman University, Adıyaman, Turkey
* Corresponding Author
J CLIN MED KAZ, Volume 19, Issue 2, pp. 43-47. https://doi.org/10.23950/jcmk/11939
OPEN ACCESS
Download Full Text (PDF)

ABSTRACT

Objective:  It was aimed to compare the serum asprosin levels in patients with ischemic heart disease with healthy subjects, and to evaluate the relationship between asprosin levels with HEART score and mortality in the patients with coronary heart disease.
Material and methods: This study was designed as a single-center, prospective study. Sixty-two patients who presented with acute chest pain and underwent digital subtraction coronary angiography and 31 healthy subjects were included in the study. Fasting serum asprosin levels were compared between patients and healthy individuals. The HEART score was calculated for each individual, and its relations with asprosin and one-month mortality were evaluated.
Results: The minimum age of 93 cases included in the study was 24, the maximum age was 85, and the median age was 64. HEART score was higher in cases who had mortality within one month (p<0.0001). Plasma asprosin values were higher in patients with one-month mortality (p<0.0001) and lower in the control group compared to the study group (p=0.015). There is a statistically significant weak positive correlation between HEART score and asprosin value (p=0.006, r=0.285).
Conclusion: Serum asprosin level can be used both diagnostically and as a biochemical marker in the evaluation of mortality and prognosis in patients with ischemic heart disease.
Key words: acute chest pain, asprosin, HEART score

CITATION

Algin A, Özdemir S, Akça HŞ, Hökenek NM, Kokulu K, Erdoğan MÖ, et al. The assessment of plasma asprosin levels in acute coronary artery disease and its correlation with HEART score. J CLIN MED KAZ. 2022;19(2):43-7. https://doi.org/10.23950/jcmk/11939

REFERENCES

  • Mazur-Bialy AI. Asprosin-A Fasting-Induced, Glucogenic, and Orexigenic Adipokine as a New Promising Player. Will It Be a New Factor in the Treatment of Obesity, Diabetes, or Infertility? A Review of the Literature. Nutrients. 2021;13(2):620. https://doi.org/10.3390/nu13020620
  • Zhang H, Hu W, Zhang G. Circulating asprosin levels are increased in patients with type 2 diabetes and associated with early-stage diabetic kidney disease. Int Urol Nephrol. 2020;52(8):1517-1522. https://doi.org/10.1007/s11255-020-02509-8
  • Ke F, Xue G, Jiang X, Li F, Lai X, Zhang M, et al. Combination of asprosin and adiponectin as a novel marker for diagnosing non-alcoholic fatty liver disease. Cytokine. 2020;134:155184. https://doi.org/10.1016/j.cyto.2020.155184
  • Luís C, Fernandes R, Soares R, von Hafe P. A state of the art review on the novel mediator asprosin in the metabolic syndrome. Porto Biomed J. 2020;5(6):e108. https://doi.org/10.1097/j.pbj.0000000000000108
  • Zhang L, Chen C, Zhou N, Fu Y, Cheng X. Circulating asprosin concentrations are increased in type 2 diabetes mellitus and independently associated with fasting glucose and triglyceride. Clinica Chimica Acta; International Journal of Clinical Chemistry. 2019;489:183-188. https://doi.org/10.1016/j.cca.2017.10.034
  • Du C, Wang C, Guan X, Li J, Du X, Xu Z, et al. Asprosin is associated with anorexia and body fat mass in cancer patients. Support Care Cancer. 2021;29(3):1369-1375. https://doi.org/10.1007/s00520-020-05621-8
  • Acara AC, Bolatkale M, Kızıloğlu İ, İbişoğlu E, Can Ç. A novel biochemical marker for predicting the severity of ACS with unstable angina pectoris: Asprosin. Am J Emerg Med. 2018;36(8):1504-1505. https://doi.org/10.1016/j.ajem.2017.12.032
  • Ke F, Xue G, Jiang X, Li F, Lai X, Zhang M, et al. Combination of asprosin and adiponectin as a novel marker for diagnosing non-alcoholic fatty liver disease. Cytokine. 2020;134:155184. https://doi.org/10.1016/j.cyto.2020.155184
  • Duerrschmid C, He Y, Wang C, Li C, Bournat JC, Romere C, et al. Asprosin is a centrally acting orexigenic hormone. Nat Med. 2017;23(12):1444-53. https://doi.org/10.1038/nm.4432
  • Zhang Z, Tan Y, Zhu L, Zhang B, Feng P, Gao E, et al. Asprosin improves the survival of mesenchymal stromal cells in myocardial infarction by inhibiting apoptosis via the activated ERK1/2-SOD2 pathway. Life Sci. 2019;231:116554. https://doi.org/10.1016/j.lfs.2019.116554
  • Yuan M, Li W, Zhu Y, Yu B, Wu J. Asprosin: A Novel Player in Metabolic Diseases. Front Endocrinol (Lausanne). 2020;11:64. https://doi.org/10.3389/fendo.2020.00064
  • Six AJ, Backus BE, Kelder JC. Chest pain in the emergency room: value of the HEART score. Neth Heart J. 2008;16(6):191- 6. https://doi.org/10.1007/BF03086144
  • Généreux P, Palmerini T, Caixeta A, Cristea E, Mehran R, Sanchez R, et al. SYNTAX score reproducibility and variability between interventional cardiologists, core laboratory technicians, and quantitative coronary measurements. Circ Cardiovasc Interv. 2011;4(6):553-61. https://doi.org/10.1161/CIRCINTERVENTIONS.111.961862
  • Laureano-Phillips J, Robinson RD, Aryal S, Blair S, Wilson D, Boyd K, et al. HEART Score Risk Stratification of Low-Risk Chest Pain Patients in the Emergency Department: A Systematic Review and Meta-Analysis. Ann Emerg Med. 2019;74(2):187-203. https://doi.org/10.1016/j.annemergmed.2018.12.010